Engflag

Flexiplen

Quick links to important sections

Flexiplen

Flexiplen_EN

Method of action: Analgesic, Analgesic Local, Analgetic, Anti-Inflammatory, Antiplatelet, Antipyretic, Antirheumatic, Decongestant, Nonsteroidal Anti-Inflammatory, Ophthalmologicals

Treatment option: Ankylosing Spondylitis, Backache, Pain, Bursitis, Headache, Influenza, Dysmenorrhea, Biliary Colic, Toothache, Colic

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flexiplen

Property Description
Active Ingredient Diclofenac (INN)
Form Varied (Tablet, Capsule, Gel, Solution)
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use Symptomatic relief of pain and inflammation
Origin Synthetic, Phenylacetic Acid Derivative

Defining Flexiplen: Identity and Pharmacological Class

Flexiplen is a commercial name for a pharmaceutical preparation containing the active ingredient Diclofenac, which is globally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification identifies it as a potent, synthetic non-narcotic analgesic, chemically derived from the phenylacetic acid family of compounds. The drug’s identity is intrinsically linked to its active core, Diclofenac, which is typically incorporated as its Sodium or Potassium salt form to ensure appropriate absorption and efficacy upon administration. Diclofenac-based products are considered a cornerstone in the management of acute inflammatory pain.

Composition and Available Forms of Diclofenac

Flexiplen is formulated as a single-ingredient product, with Diclofenac being the only pharmacologically active substance. The compound’s versatility allows it to be manufactured into a broad array of high-level dosage forms, including oral preparations like tablets and capsules, as well as topical preparations such as gels and patches, and liquid solutions. This variety in formulation determines the appropriate route of administration, which may be oral, topical, or parenteral. Diclofenac formulations are frequently differentiated by their salt type—Sodium or Potassium—which influences the speed of therapeutic onset.

General Therapeutic Purpose and Action (High-Level Benefit)

The core therapeutic purpose of Flexiplen is to provide essential symptomatic relief by mitigating pain and inflammation. The medicine achieves this general benefit by exerting simultaneous anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) effects. For instance, a patient may utilize this type of medication to alleviate the pain and swelling associated with soft tissue irritation. Diclofenac is characterized by its anti-inflammatory and analgesic efficacy. This capability allows the drug to effectively reduce swelling and alleviate discomfort without employing opioid-based compounds for pain management.

Regulatory References

  1. Diclofenac - StatPearls - NCBI Bookshelf

What side effects are possible with Flexiplen?

Flexiplen (Diclofenac) has an official safety profile, documented by governmental health authorities, which organizes adverse reactions by frequency and the physiological system affected. The profile highlights potential risks related to the drug's classification as a Non-Steroidal Anti-Inflammatory Drug (NSAID).

Official Adverse Reaction Classifications

Adverse reactions are formally grouped into System-Organ Classes (SOCs), with effects documented across Gastrointestinal Disorders, Cardiovascular System Disorders, Nervous System Disorders, Hepatobiliary Disorders, and Skin and Subcutaneous Tissue Disorders. Common side effects, as defined by regulatory frequency standards, often include nausea, vomiting, diarrhea, dyspepsia, abdominal pain, headache, and dizziness.

Serious Adverse Reactions and Safety Constraints

The regulatory documentation emphasizes the risk of serious adverse reactions. These include potentially fatal cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal bleeding, ulceration, or perforation. These serious GI events can occur at any time during treatment and may occur without prior warning symptoms. The risk of cardiovascular thrombotic events is officially noted to increase with both the duration of use and dose.

Population-Specific Safety Notes

The official labeling notes that older adults are at a greater risk for serious gastrointestinal adverse events, which often have more severe consequences in this population. The medication is formally contraindicated for pain management following Coronary Artery Bypass Graft (CABG) surgery and in patients with a history of allergic-type reactions to other NSAIDs or aspirin. Additionally, use is generally avoided in patients with established severe heart failure or advanced renal disease, unless deemed strictly necessary.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Flexiplen

Overdose Scope

Documented overdose presentations:

  • Gastrointestinal: Nausea, vomiting (potentially with blood), epigastric pain, diarrhea, and internal bleeding.
  • Central Nervous System (CNS): Dizziness, drowsiness, headache, tinnitus, blurred vision, agitation, confusion, seizures, and coma.

Physiological systems affected (as stated in label):

  • Gastrointestinal system
  • Central Nervous System (CNS)
  • Renal (Kidney) system
  • Hepatic (Liver) system

Dose-related or exposure-related factors (if applicable):

  • Severity of manifestations, including the occurrence of seizures and coma, is typically associated with very large or severe overdose.

Population-specific overdose notes (if applicable):

  • Overdose consequences, particularly severe GI bleeding and cardiovascular events, are documented as more serious in the elderly.
  • Increased risk of severe outcomes in patients with pre-existing asthma or renal/hepatic impairment.

Emergency-response statements (as written in official documents):

  • Treatment is symptomatic and supportive; no specific antidote is known.
  • Management procedures may include Activated Charcoal or Gastric Lavage in early, significant ingestions.

When immediate medical help is required (label-derived phrasing only):

  • Seek immediate medical attention for any suspected overdose.
  • Contact emergency services immediately for signs of severe outcomes, including seizures, coma, acute renal failure, or signs of internal bleeding.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents):

  • Ranging from common gastrointestinal disturbance to severe and life-threatening outcomes (e.g., fatal GI perforation, acute renal failure, coma).

Regulatory basis (EMA / FDA / etc.):

  • Based on the official prescribing information as documented by governmental regulatory authorities.

Overdose-context constraints (as defined in official documents):

  • Management is limited to supporting vital functions and treating specific symptoms as they arise.

Resulting Overdose Structure

Official overdose statements:

  • Nausea, vomiting, epigastric pain, and drowsiness are commonly documented manifestations.
  • Severe outcomes include acute renal failure, seizures, coma, and potentially fatal gastrointestinal perforation.
  • Immediate medical attention must be sought due to the risk of life-threatening events.
  • No specific antidote is known; treatment relies on supportive care.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile through documented manifestations, ranging from common GI effects to severe systemic events like acute renal failure and seizures. This profile immediately mandates seeking medical attention due to the high risk of life-threatening complications, especially internal bleeding and CNS depression. Since regulatory sources confirm the absence of a specific antidote, management centers on officially described supportive care and continuous hospital monitoring to manage adverse physiological changes as they present.

Therapeutic Uses of Flexiplen

Flexiplen is an approved medication intended for the management of various inflammatory conditions and associated pain. Its primary role is to help address symptoms, particularly those involving the musculoskeletal system.

Quick Facts: Flexiplen Benefits

  • Relief of Discomfort: May provide relief from mild to moderate pain.
  • Inflammatory Conditions: Indicated for the management of symptoms associated with specific inflammatory joint conditions, such as osteoarthritis and rheumatoid arthritis.
  • Musculoskeletal Support: Designed to help manage pain in the joints and muscles.

The medication is a therapeutic option for patients seeking symptom management of acute and chronic pain. It is an established compound within this class of therapy. Flexiplen is not intended to reverse chronic damage, but rather to modulate the inflammatory process to support patient comfort and overall function.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Flexiplen (diclofenac) is a Non-Steroidal Anti-Inflammatory Drug (NSAID) whose use is governed by official eligibility constraints established by regulatory bodies.

Populations Who Must Not Use Flexiplen (Contraindications)

Use of this medicine is strictly contraindicated for individuals with several key conditions, as they pose a high risk for serious adverse events. These include:

  • Hypersensitivity: A known allergy to the active substance, or a history of asthma, urticaria, or allergic reactions triggered by aspirin or other NSAIDs.
  • Gastrointestinal (GI) Disease: The presence of an active gastric or intestinal ulcer, bleeding, or perforation, or a history of recurrent peptic ulceration or GI hemorrhage related to previous NSAID therapy.
  • Cardiovascular Disease: Established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease. It is also contraindicated for the treatment of pain right before or after coronary artery bypass graft (CABG) surgery.
  • Organ Failure: Severe hepatic failure or severe renal failure.
  • Pregnancy Status: Use is strictly prohibited during the last trimester of pregnancy.

Eligibility Restrictions and Special Considerations

  • Age: Use is generally not recommended for children and adolescents under 14 years of age (depending on the formulation). The elderly require special caution due to an increased risk of serious gastrointestinal, cardiovascular, and renal complications.
  • Condition: Patients with mild-to-moderate cardiac, hepatic, or renal impairment, or with conditions like Ulcerative Colitis or Crohn’s disease, should use this medicine only after careful consideration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flexiplen's interaction profile is based strictly on pharmacokinetic and pharmacodynamic patterns documented in regulatory sources.

Interaction Classifications and Restrictions

Classification Interacting Agents / Conditions Official Interaction Pattern
Contraindicated Combinations Aspirin, Other NSAIDs Pharmacodynamic interaction that substantially increases the risk of serious gastrointestinal and renal adverse events.
CABG Surgery (Peri-operative pain) Use is restricted due to increased cardiovascular thrombotic risk.
Exposure Modification Lithium, Methotrexate Diclofenac reduces the renal clearance of these drugs, leading to elevated plasma concentrations.
Voriconazole (CYP2C9 inhibitor) Pharmacokinetic interaction that significantly increases Diclofenac's systemic exposure (Cmax and AUC).
Additive Toxicity Risk Anticoagulants, SSRIs/SNRIs Pharmacodynamic interaction that increases the official risk of serious gastrointestinal bleeding.
Cyclosporine May increase the risk of Cyclosporine-induced nephrotoxicity (kidney problems).
Diminished Efficacy ACE Inhibitors, Diuretics May diminish the antihypertensive or diuretic effects of these co-administered agents.

Timing and Population Notes

Administration restrictions apply to certain formulations; for instance, some forms may have reduced absorption when taken with food. Co-administration with bile acid sequestrants (e.g., Cholestyramine) may also require separation in time to mitigate reduced Diclofenac exposure. Consumption of alcohol increases the additive risk of gastrointestinal toxicity. Regulatory documentation notes that elderly patients are more susceptible to the severe consequences of many of these interactions.

Mechanism of Action

Flexiplen (Diclofenac) exerts its effects through a highly specific biological mechanism: the modulation of eicosanoid signaling by inhibiting the Cyclooxygenase ( COX) enzyme system. This targeted molecular action engages mechanisms that modulate physiological responses at both peripheral and central levels.

The drug's primary mechanism involves the non-selective, reversible inhibition of both COX-1 and COX-2 enzymes. This action suppresses the synthesis of Prostaglandins ( PGs) from Arachidonic Acid, thereby modifying early molecular steps that influence physiological events. PGs function as key mediators in the signaling cascade of nociception and inflammatory responses.

By suppressing PGE2 production, the drug affects systems where this mediator dominates, leading to alterations in physiological signaling. In the periphery, this action increases the threshold of peripheral nociceptor activation by desensitizing pain fibers; centrally, the reduced PGE2 concentration within the hypothalamus results in the modulation of an elevated temperature set-point. This modulation achieves altered signaling dynamics within the targeted pathways.

Dosage and Administration Information

The use of Flexiplen (Diclofenac) is organized across multiple formulations and administration pathways. The core principle for all use is to administer the lowest effective dosage for the shortest duration consistent with individual goals.

Official Routes and Dose Principles

Flexiplen is approved for various routes, including Oral (tablets, capsules, powder), Topical (gels, solutions), and Parenteral (intramuscular and intravenous injection/infusion).

Administration Route Standard Dosing Frequency (Adult) Key Labeled Instruction
Oral (Delayed/IR) Two to four times daily Tablets must be swallowed whole; do not crush, split, or chew.
Oral (Powder for Solution) As a single dose (e.g., for acute use) Mix with 1 to 2 ounces of water only and drink immediately, often taken on an empty stomach.
Topical Gel (1%) Four times daily Measured using the dosing card supplied; total daily dose should not exceed 32 g over all affected joints.
Parenteral (IM/IV) Once or twice daily IV solution must be diluted and buffered before infusion; parenteral use is typically limited to a short course, such as two days.

Population and Administration Context

For older adults, the initial dose is generally advised to be the lowest effective dosage. If a scheduled oral dose is missed, it should be skipped if it is almost time for the next dose; a double dose should not be taken to compensate. This structured approach ensures administration is aligned with the specific formulation and intended route.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flexiplen

This section describes the types of clinical studies conducted on Flexiplen (Diclofenac) and what aspects of its use were monitored in research settings. It summarizes the existing evidence structure without offering clinical advice or personal recommendations.

Evidence for Use in Osteoarthritis Management

Research examining the use of Flexiplen for managing symptoms associated with joint discomfort and stiffness is supported by substantial research, including Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were used in research exploring how symptoms change over time in adults with diagnosed osteoarthritis (OA), with a studied focus on the knee or hip joints. Researchers primarily examined patient-reported outcomes describing perceived discomfort, specifically monitoring changes in pain intensity, joint stiffness, and outcomes reflecting daily functioning.

Evidence for Chronic and Acute Conditions

Flexiplen was evaluated in settings involving chronic systemic inflammatory joint diseases, specifically Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). These studies monitored the medicine's use in the context of symptomatic management, examining outcomes linked to inflammatory states, such as joint swelling and changes in disease activity scores. Studies contribute to the broader evidence landscape for these conditions.

Research on acute pain focused on short-duration changes in symptom measurements. These studies are typically relevant in trials assessing short-term or episodic symptom patterns and are designed to measure the time to onset of noticeable symptomatic change. However, follow-up durations were limited in many acute pain trials, often lasting only a few hours up to three days.

Evidence Gaps and Uncertainty

The research for certain patient groups remains constrained. Studies examined data for older adults (65 years) with conditions marked by functional limitations, but data for certain groups remain insufficient, including children or adolescents. When considering sustained use, long-term effects are not fully established by the same rigorous standard of continuous single-treatment RCTs that characterize the initial short-term research. Therefore, there is a persistent need for dedicated, long-duration studies to fully explore patterns related to symptom changes over several years of continuous use.

Frequently Asked Questions (FAQ)

Common questions about Flexiplen (FAQ)

Q: If I take Flexiplen for a sprain, how long does it take for the pain relief to start working?

Official information indicates that oral forms of this medication, such as tablets and capsules, generally begin to work for pain relief within 20 to 30 minutes of being taken. Topical forms, which include gels, plasters, and patches, may require a longer time before noticeable pain relief is reported. The onset of action can vary by formulation.

Q: What should I do if I accidentally miss a dose of my Flexiplen tablet?

Regulatory labeling indicates that if a scheduled oral dose is missed and it is nearly time for the next dose, the missed dose is typically skipped, and the regular schedule is resumed. Official guidance cautions against taking two doses at once to compensate. The same principle applies to topical applications: skip the missed dose if the next one is due soon and do not apply extra medicine.

Q: Is it safe to drink alcohol while I am taking Flexiplen?

Regulatory documents strongly caution against consuming alcohol while taking this medicine. This is because alcohol use significantly increases the additive risk of serious gastrointestinal side effects, such as irritation and internal bleeding. Information regarding alcohol consumption should be reviewed with a healthcare professional.

Q: What are the signs or symptoms of an overdose of Flexiplen, and what should I do?

Regulatory documents note that possible signs of taking too much of this medicine may include nausea, vomiting, stomach pain, or feeling drowsy. In rare but serious cases, symptoms can involve bloody stools or loss of consciousness. Official product information indicates that emergency medical services should be contacted immediately in the event of a suspected overdose.

Q: Can I use Flexiplen while breastfeeding?

Official information from health authorities suggests that only tiny amounts of the active ingredient pass into breast milk, making it a generally preferred option among Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Use of this medicine while breastfeeding should be confirmed with a healthcare professional to ensure appropriate management. Special care is noted when using topical forms to prevent the baby from contacting the treated skin area.

Q: Can Flexiplen be cut in half to adjust the dose?

Many of the oral tablets and capsules for this medicine are specifically designed to be swallowed whole and should not be crushed, split, or chewed. Splitting certain types of tablets, such as those that are extended-release or specially coated, can alter how the medicine is absorbed by the body. The medicine is intended to be taken as directed by the prescribing professional.

How should Flexiplen be stored and disposed of?

How to Store and Dispose of Flexiplen?

The official labeling for Flexiplen details mandatory requirements for storage, handling, and disposal.

Storage Requirements

Storage Classification Requirement
Temperature Store unopened product at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Prohibitions Do not freeze. Do not store above 30 C (86 F).
Protection Keep in the original carton to protect from light. Keep out of the sight and reach of children.
In-Use Stability After first opening or puncturing, the product is stable for a defined period (e.g., 28 days) when stored correctly.

Disposal Instructions

Unused or expired Flexiplen must not be disposed of in household trash or poured down sinks or toilets. Regulatory documents mandate that disposal must adhere to local pharmaceutical waste collection guidelines. All used sharps, such as needles or injection pens, must be immediately placed in an FDA-cleared, puncture-resistant sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Flexiplen found in:

A-Z Index: